CN109616208A - 一种评估肠道菌群紊乱程度的分析技术 - Google Patents

一种评估肠道菌群紊乱程度的分析技术 Download PDF

Info

Publication number
CN109616208A
CN109616208A CN201811538972.0A CN201811538972A CN109616208A CN 109616208 A CN109616208 A CN 109616208A CN 201811538972 A CN201811538972 A CN 201811538972A CN 109616208 A CN109616208 A CN 109616208A
Authority
CN
China
Prior art keywords
dys
relative abundance
disturbance degree
enteric flora
flora disturbance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811538972.0A
Other languages
English (en)
Inventor
倪加加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Kang Beauty Biotechnology Co Ltd
Original Assignee
Guangdong Kang Beauty Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Kang Beauty Biotechnology Co Ltd filed Critical Guangdong Kang Beauty Biotechnology Co Ltd
Priority to CN201811538972.0A priority Critical patent/CN109616208A/zh
Publication of CN109616208A publication Critical patent/CN109616208A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明公开了一种评估肠道菌群紊乱程度（D dys ）的分析技术。通过选用与代谢疾病密切相关的7个肠道益生菌属和13个肠道有害菌属在肠道菌群中的相对丰度作为计算依据，根据公式D dys=Σ(log10(100×有害菌相对丰度+1))‑Σ(log10(100×益生菌相对丰度+1))计算肠道菌群紊乱程度（D dys ）。利用本发明提供的评估技术能够有效评估肠道菌群的紊乱程度，为根据肠道菌群紊乱程度进行代谢性疾病诊断提供重要参考。

Description

一种评估肠道菌群紊乱程度的分析技术
技术领域
本发明设计分子诊断领域，具体涉及评估肠道菌群健康程度的分析技术，尤其是评估肠道菌群紊乱程度的分析技术。
背景技术
脊椎动物肠道菌群中生存着大量的微生物，它们在宿主的消化吸收、生长发育、免疫健康等方面都发挥重要作用。肠道菌群紊乱与包括肥胖、2型糖尿病、脂肪肝、肝细胞癌等在内的宿主代谢性疾病密切相关。尽管肠道菌群紊乱被经常提及，但是目前多数情况下都是将患病宿主肠道菌群与健康对照的肠道菌群进行比较，如果存在差异就认为患病宿主肠道菌群存在紊乱，并没有一种合理评估肠道菌群紊乱程度的技术方法。
肠道菌群紊乱即肠道菌群中益生菌与有害菌相对丰度失衡，这种失衡程度的多少决定了肠道菌群紊乱程度的大小。尽管目前已经积累了大量肠道菌群中主要的益生菌和有害菌的研究资料，并且已经明确了Bifidobacterium、Lactobacillus等益生菌在肠道物质代谢和有益物质合成方面的作用，以及Bacteroides、Clostridium、Ruminococcus和Streptococcus等在引发宿主炎症和代谢紊乱中的作用。但是如何通过计算益生菌和有害菌相对比例评价肠道菌群紊乱目前也没有明确的技术方法。本发明通过肠道菌群中常见的7个益生菌属和13个有害菌属在肠道菌群中的相对丰度作为计算依据，建立了一种评估肠道菌群紊乱程度的分析技术。
发明内容
本发明要解决的问题是定量评价肠道菌群的紊乱程度问题。利用本发明提供的计算方法，能够准确计算长度菌群的紊乱程度。
本发明的具体实施步骤为：（1）选用肠道菌群中常见的7个益生菌属（Anaerostipes、Bifidobacterium、Coprococcus、Faecalibacterium、Lactobacillus、Oscillibacter和Phascolarctobacterium）和13个有害菌属（Akkermansia、Bacteroides、Clostridium、Dorea、Escherichia、Fusobacterium、Haemophilus、Helicobacter、Klebsiella、Prevotella、Ruminococcus、Streptococcus和 Veillonella）在肠道菌群中的相对丰度作为计算基础。（2）根据公式D dys = Σ(log10(100 × 有害菌相对丰度 + 1)) - Σ(log10(100 × 益生菌相对丰度 + 1))计算肠道菌群紊乱程度（D dys ）（图2）。
采用上述分析方案所产生的有益效果在于：能够计算得到准确的肠道菌群紊乱程度（D dys ）指标。
附图说明
图1简要介绍评估肠道菌群紊乱程度的量化指标分析流程。
图2是本发明的分析流程图。
图3是实施例1中采用本分析技术得到的不同分期肝细胞癌患者和健康对照人群肠道菌群紊乱程度结果。*表示均值之间存在显著差异；**表示均值之间存在极显著差异。
具体实施方式
以下实施是对本发明的进一步说明，而不是对本发明技术参数的限制。
实施例1
采用本分析技术对23例I期肝细胞癌患者、13例II期肝细胞癌患者、30例III期肝细胞癌患者和18例健康对照人群肠道菌群紊乱程度进行计算。I期肝细胞癌患者肠道菌群紊乱指数平均为0.770 ± 0.213（平均值±标准误），II期肝细胞癌患者肠道菌群紊乱指数平均为1.119 ± 0.244，III期肝细胞癌患者肠道菌群紊乱指数平均为1.188 ± 0.208，而正常对照组的肠道菌群紊乱指数平均为0.096 ± 0.194（图3）。

Claims (4)

1.一种评估肠道菌群紊乱程度（D dys ）的分析技术，其特征是：选用与代谢疾病密切相关的7个肠道益生菌属和13个肠道有害菌属在肠道菌群中的相对丰度作为计算依据，根据公式D dys = Σ(log10(100 × 有害菌相对丰度 + 1)) - Σ(log10(100 × 益生菌相对丰度 +1))计算肠道菌群紊乱程度（D dys ）。
2.权利要求书1所述的评估肠道菌群紊乱程度（D dys ）的分析技术，其特征在于：所选用的7个肠道益生菌属为Anaerostipes、Bifidobacterium、Coprococcus、Faecalibacterium、Lactobacillus、Oscillibacter和Phascolarctobacterium。
3.权利要求书1所述的评估肠道菌群紊乱程度（D dys ）的分析技术，其特征在于：所选用的13个有害菌属为Akkermansia、Bacteroides、Clostridium、Dorea、Escherichia、Fusobacterium、Haemophilus、Helicobacter、Klebsiella、Prevotella、Ruminococcus、Streptococcus和 Veillonella。
4.权利要求书1所述的评估肠道菌群紊乱程度（D dys ）的分析技术，其特征在于：根据所选用的菌属相对丰度计算肠道菌群紊乱程度（D dys ）时，相对丰度应根据公式log10(100 ×有害菌相对丰度 + 1)或者log10(100 × 益生菌相对丰度 + 1)进行对数转换。
CN201811538972.0A 2018-12-17 2018-12-17 一种评估肠道菌群紊乱程度的分析技术 Pending CN109616208A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811538972.0A CN109616208A (zh) 2018-12-17 2018-12-17 一种评估肠道菌群紊乱程度的分析技术

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811538972.0A CN109616208A (zh) 2018-12-17 2018-12-17 一种评估肠道菌群紊乱程度的分析技术

Publications (1)

Publication Number Publication Date
CN109616208A true CN109616208A (zh) 2019-04-12

Family

ID=66010112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811538972.0A Pending CN109616208A (zh) 2018-12-17 2018-12-17 一种评估肠道菌群紊乱程度的分析技术

Country Status (1)

Country Link
CN (1) CN109616208A (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110060778A (zh) * 2019-04-23 2019-07-26 完美(上海)健康科技有限公司 以肠道菌群为靶点的健康管理方案
CN110511990A (zh) * 2019-09-12 2019-11-29 广东美立康生物科技有限公司 一种棘胸蛙蝌蚪变态期死亡风险预测技术
CN112435756A (zh) * 2020-11-30 2021-03-02 武汉益鼎天养生物科技有限公司 基于多数据集差异互证的肠道菌群关联疾病风险预测系统

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110060778A (zh) * 2019-04-23 2019-07-26 完美(上海)健康科技有限公司 以肠道菌群为靶点的健康管理方案
CN110511990A (zh) * 2019-09-12 2019-11-29 广东美立康生物科技有限公司 一种棘胸蛙蝌蚪变态期死亡风险预测技术
CN112435756A (zh) * 2020-11-30 2021-03-02 武汉益鼎天养生物科技有限公司 基于多数据集差异互证的肠道菌群关联疾病风险预测系统
CN112435756B (zh) * 2020-11-30 2024-02-09 武汉益鼎天养生物科技有限公司 基于多数据集差异互证的肠道菌群关联疾病风险预测系统

Similar Documents

Publication Publication Date Title
Magne et al. The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients?
Murtaza et al. The effects of dietary pattern during intensified training on stool microbiota of elite race walkers
Knuesel et al. The role of the gut microbiota in the development and progression of major depressive and bipolar disorder
Shoaie et al. Elucidating the interactions between the human gut microbiota and its host through metabolic modeling
CN109616208A (zh) 一种评估肠道菌群紊乱程度的分析技术
Chen et al. Psychophysiological effects of Lactobacillus plantarum PS128 in Patients with major depressive disorder: A preliminary 8-week open trial
Ganda Mall et al. Effects of dietary fibres on acute indomethacin-induced intestinal hyperpermeability in the elderly: a randomised placebo controlled parallel clinical trial
Méndez-García et al. Ten-week sucralose consumption induces gut dysbiosis and altered glucose and insulin levels in healthy young adults
Sugawara et al. Daily intake of paraprobiotic Lactobacillus amylovorus CP1563 improves pre-obese conditions and affects the gut microbial community in healthy pre-obese subjects: a double-blind, randomized, placebo-controlled study
Ozato et al. Two Blautia species associated with visceral fat accumulation: a one-year longitudinal study
Seo et al. Methanobrevibacter attenuation via probiotic intervention reduces flatulence in adult human: a non-randomised paired-design clinical trial of efficacy
Porzi et al. Development of personalized nutrition: applications in lactose intolerance diagnosis and management
Oh et al. Characterization of gut microbiome in Korean patients with metabolic associated fatty liver disease
Mompeo et al. Consumption of stilbenes and flavonoids is linked to reduced risk of obesity independently of fiber intake
Hric et al. The efficacy of short-term weight loss programs and consumption of natural probiotic bryndza cheese on gut microbiota composition in women
Hasain et al. The roles of probiotics in the gut microbiota composition and metabolic outcomes in asymptomatic post-gestational diabetes women: a randomized controlled trial
Han et al. Comparison of the diagnostic performance of steatosis indices for discrimination of CT-diagnosed metabolic dysfunction-associated fatty liver disease
Gold et al. Effects of an amino acid-based formula supplemented with two human milk oligosaccharides on growth, tolerability, safety, and gut microbiome in infants with cow’s milk protein allergy
Olbjørn et al. Targeted analysis of the gut microbiome for diagnosis, prognosis and treatment individualization in pediatric inflammatory bowel disease
Johnstone et al. Nutrient intake and gut microbial genera changes after a 4-week placebo controlled galacto-oligosaccharides intervention in young females
Ramai et al. Hospital frailty risk score is independently associated with mortality and encephalopathy in hospitalized patients with hepatocellular carcinoma
Manabe et al. Usefulness of the measurement of psoas muscle volume for sarcopenia diagnosis in patients with liver disease
Puca et al. Role of Multiparametric Intestinal Ultrasound in the Evaluation of Response to Biologic Therapy in Adults with Crohn’s Disease
Han et al. Exploring the differences in the gut microbiome in atopic dermatitis according to the presence of gastrointestinal symptoms
Matsumoto et al. Relationship between nutrient intake and human gut microbiota in monozygotic twins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190412

WD01 Invention patent application deemed withdrawn after publication